OncLive TV

James Kearns, MD, assistant professor of urology, Levine Cancer Institute, discusses the role of surgery in patients with high-risk prostate cancer.

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential for precision medicine in hepatocellular carcinoma.

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia (CHOP), discusses frontline therapy for pediatric patients with Ph-like acute lymphoblastic leukemia (ALL).

Balazs Halmos, MD, MS, director of thoracic oncology and director of clinical cancer genomics, Montefiore Medical Center, discusses the use of immunotherapy in the treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC).

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses EGFR-targeted therapies in non–small cell lung cancer.

William J. Gradishar, MD, chief of hematology and oncology, Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Northwestern University's Feinberg School of Medicine, discusses the rise of personalized treatment in breast cancer.

Lloyd Damon, MD, director of the Adult Blood and Marrow Transplant and Hematologic Malignancies Program, and chief of the University of California, San Francisco (UCSF) Hematology Clinic, UCSF Helen Diller Family Comprehensive Cancer Center, discusses drug development in acute myeloid leukemia (AML).

P. Cosmo Smith, MBA, managing partner, Origin Commercial Ventures, discusses The Breakthrough Oncology Accelerator flagship program.

Natasha Leighl, MD, medical oncologist, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, discusses binimetinib (Mektovi) in KRAS-mutated non–small cell lung cancer.

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the next steps of the St. Jude Lifetime Cohort Study.

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses surgical approaches in breast cancer.

Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, assistant professor of oncology, University of South Florida, discusses the challenges of developing clinical trials for CAR T cells in mantle cell lymphoma.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses eliminating financial toxicity in oncology.

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the status of biosimilars in oncology.

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the FDA approval of talazoparib (Talzenna) for the treatment of patients with germline BRCA mutation–positive, HER2-negative locally advanced or metastatic breast cancer

Keith Kerr, BSc, MB, ChB, consultant pathologist, University of Aberdeen, Aberdeen, Scotland, discusses common misconceptions with molecular profiling in lung cancer.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with relapsed/refractory mantle cell lymphoma.

Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the role of smoking status in the diagnosis of bladder cancer.

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses next steps with atezolizumab (Tecentriq) in small cell lung cancer.

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses response to chimeric antigen receptor (CAR) T-cell therapy.

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of carfilzomib (Kyprolis) in the treatment of patients with multiple myeloma.

Susana M. Campos, MD, gynecologic oncologist, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses next steps with PARP inhibitors in ovarian cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer, a 2017 Giant of Cancer Care in Lung Cancer®, discusses practice-changing studies in lung cancer.

Jill O'Donnell-Tormey, PhD, chief executive officer, director of scientific affairs, Cancer Research Institute, discusses the importance of curiosity in expanding the role of immunology in the treatment of cancer.

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses outcomes for children enrolled on the SJYC07 trial.

Padmanee Sharma, MD, PhD, professor of Immunology in the Department of Genitourinary Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses immune checkpoint resistance in genitourinary cancers.

Jonathon B. Cohen, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute of Emory University, discusses combination therapy for patients with mantle cell lymphoma.

P. Cosmo Smith, managing partner, Origin Commercial Ventures, discusses how Origin improves patient access in oncology.